Here are highlights from Tuesday’s Analyst Blog:
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
Trump’s Funding Cuts Halt Rollout Of HIV Prevention Drug
A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...
Hosted on MSN19h
Gilead’s lenacapavir applications for HIV gain EMA validation
Gilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...
Something Unexpected Is Spewing Stars Into the Milky Way
Fast-moving stars in the Milky Way indicate there could be a supermassive black hole in the neighboring Large Magellanic ...
DOGE Is Working on Software That Automates the Firing of Government Workers
Operatives working for Elon Musk’s DOGE appear to be editing the code of AutoRIF—software designed by the Defense Department ...
Morgan Stanley sees FDA approval of GILD's Lenacapavir
Morgan Stanley expects the FDA to approve Gilead Sciences (NASDAQ:GILD)' Lenacapavir (LEN) for HIV prevention (PrEP) on or before its June 19 PDUFA date, a move that the bank believes could drive ...